2023-11-05 13:29:04
A vaccination stops cancer growth
Mr. Alexander Zehnder, the new CEO of Curevac, a leading mRNA pioneer, recently discussed the potential of mRNA technology in fighting diseases other than COVID-19. He emphasized the importance of mRNA vaccines and revealed that Curevac is currently working on a double vaccination against influenza and coronavirus, as well as a revolution in cancer treatment.
Curevac was once considered the most promising candidate for the first COVID-19 vaccine but failed to gain approval. However, under the leadership of Mr. Zehnder, the company aims to bring a cancer vaccine to market by 2028. When asked how a cancer vaccine would work, Mr. Zehnder explained that it would be similar to conventional vaccinations in teaching the immune system to recognize and fight cancer.
The potential of a preventive vaccination against lung cancer was also discussed. Mr. Zehnder confirmed that it is possible, but such a vaccine would mainly be for patients at high risk of developing cancer. However, the road to a preventive vaccination is still long. In the meantime, Curevac is focusing on developing a cancer vaccine that could be used to treat people who are already sick.
Compared to traditional cancer treatments like chemotherapy or radiation therapy, which often have numerous side effects, mRNA-based cancer vaccines have an advantage. They stimulate the immune system to specifically fight cancer cells, reducing damage to healthy tissue.
When asked if cancer vaccines can cure cancer, Mr. Zehnder responded that they can contain the disease and stop its growth, even if it has metastasized. The goal is to transform cancer into a chronic disease that patients can live with for decades, rather than it being a death sentence.
However, Mr. Zehnder clarified that personalized cancer drugs, including mRNA-based vaccines, will not be available in pharmacies. Each tumor is different, and Curevac is collaborating with companies like Moderna and Biontech to develop personalized cancer drugs. They are even building a large drug printer that can create vaccines tailored to individual patients based on their tumor characteristics.
Although this may sound like science fiction, Mr. Zehnder explained that they are working with companies like Tesla to provide the necessary technology. The prototype of the drug printer is already in their factory at Ti headquarters in Bingen, awaiting approval.
Commenting on the breakthrough potential of Curevac’s cancer treatment, Mr. Zehnder acknowledged that research into cancer vaccines has been ongoing for 20 years. However, recent progress, particularly in the field of artificial intelligence in mRNA programming, has been significant. He expressed confidence in the experience gained and the potential of mRNA technology to revolutionize cancer treatment.
In conclusion, while mRNA vaccines have been crucial in addressing the COVID-19 pandemic, they also hold promise in the fight against other diseases, including cancer. Curevac, under the leadership of Alexander Zehnder, aims to develop a cancer vaccine that can contain the disease, providing hope for patients and transforming cancer into a manageable chronic condition.
Cover photo: aussiedlerbote.de
Read more: (link to related articles)]
#vaccination #stops #cancer #growth